Although many of the available studies address the incidence
of clinically relevant (symptomatic) A-HF, emerging
data support the presence of subclinical (lacking
overt clinical symptoms but with underlying measurable
cardiac dysfunction) diastolic and systolic myocardial abnormalities
in a majority (up to 60%) of patients, even at
low cumulative doses (100 mg/m2).